Paxman AB logo

Paxman AB (B0F)

Market Open
7 Aug, 20:00
XFRA XFRA
4. 20
+0.12
+2.8186%
119.29M Market Cap
- P/E Ratio
- Div Yield
42 Volume
- Eps
4.08
Previous Close
Add Transaction
Day Range
4.2 4.2
Year Range
3.97 7.46
Want to track B0F and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

B0F trading today higher at €4.2, an increase of 2.8186% from yesterday's close, completing a monthly decrease of -3.6739% or -€0.16. Over the past 12 months, B0F stock lost -17.7451%.
B0F is not paying dividends to its shareholders.
The last earnings report, released on May 23, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on XSTO (SEK).

B0F Chart

People also search for

722
Antengene Corporation Limited
0.51
+10.7456%
7W3
Acotec Scientific Holdings Limited
0.83
+2.454%
Flerie AB (publ)
1.72
+0.2915%
R9Z
Immuneonco Biopharmaceutical Inc.
0.35
+6.0606%
25E
Elan Corporation plc
3.9
-1.0152%

Paxman AB (B0F) FAQ

What is the stock price today?

The current price is €4.20.

On which exchange is it traded?

Paxman AB is listed on XFRA.

What is its stock symbol?

The ticker symbol is B0F.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 119.29M.

Has Paxman AB ever had a stock split?

No, there has never been a stock split.

Paxman AB Profile

Health Care Technology Industry
Healthcare Sector
Richard Paxman CEO
XFRA Exchange
SE0009806284 ISIN
SE Country
105 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Paxman AB (publ) is a pioneering company founded in 1996, with its headquarters situated in Karlshamn, Sweden. It operates globally, focusing on the development and sale of its flagship Paxman scalp cooling system. This innovative system is designed to significantly reduce hair loss associated with chemotherapy treatments, a common and distressing side effect for many cancer patients. Paxman AB not only delivers its solutions to a wide range of cancer centers and hospitals around the world but also partners in research collaboration agreements, such as with the National University Hospital, Singapore, to develop advanced medical devices. Through its dedicated efforts and groundbreaking products, Paxman AB (publ) empowers cancer patients to retain their dignity and confidence during challenging times.

Products and Services

  • Paxman Scalp Cooling System

At the heart of Paxman AB's product line is the Paxman Scalp Cooling System. This state-of-the-art system is ingeniously designed to prevent the hair loss commonly induced by chemotherapy treatments in cancer patients. Through the application of controlled cooling to the scalp, it reduces the temperature of the scalp and hence diminishes the amount of chemotherapy medication that reaches the hair follicles. This product has gained worldwide recognition for its effectiveness, becoming a much-valued solution in numerous cancer centers and hospitals globally.

  • Research Collaboration

Paxman has also entered into a research collaboration agreement with the National University Hospital, Singapore. This partnership focuses on the development of a next-generation portable cooling and compression device. Through this venture, Paxman AB is at the forefront of innovation in medical technology, seeking to expand its product line and offer new solutions that alleviate the side effects of cancer treatments and improve the quality of life for patients undergoing such treatments.

Contact Information

Address: Pirgatan 13
Phone: +46 8 506 363 40